Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Creatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 17/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 17/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Creatine SCHEMBL4269044 | 1.00 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL5569335 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL4885845 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL3807770 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL675800 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL7858043 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL6673726 | 0.95 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL9391271 | 0.93 | CA1 (0.41) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL1065566 | 0.92 | NOS3 (0.39) | CA1CA2NOS3NOS1NOS2 | |
| Creatine SCHEMBL939498 | 0.90 | CA1 (0.37) | CA1CA2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118652716-B | Composite ferrous sulfide passivating agent and preparation method thereof | 淄博康业环保科技有限公司 | 2025-01-28 | — | — | CN | claimed |
| US-7226947-B1 | Use of creatine as a fat substitute | ALZCHEM TROSTBERG GMBH (DE) | 2007-06-05 | — | — | US | claimed |
| EP-1176875-B1 | USE OF CREATINE AS A FEED SUBSTITUTE | DSM FINE CHEM AUSTRIA GMBH (AT) | 2005-01-19 | — | — | EP | claimed |
| CN-119798120-A | Preparation method of creatine monohydrate | 安徽泰格生物科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-118652716-B | Composite ferrous sulfide passivating agent and preparation method thereof | 淄博康业环保科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118955333-A | Creatine monohydrate production system and production method | 宁夏恒康科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118652716-A | Composite ferrous sulfide passivating agent and preparation method thereof | 淄博康业环保科技有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-117529554-A | Enzyme agent comprising transglutaminase and use thereof | 天野酶制品株式会社 | 2024-02-06 | — | — | CN | disclosed |
| CN-114426965-B | Kit for simultaneously extracting DNA, RNA and protein from plant tissue sample and general method | 深圳华大生命科学研究院 | 2023-12-26 | — | — | CN | disclosed |
| CN-113545996-B | Protein product capable of fixing target object and being removed according to need | 西安曼特思生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230331868-A1 | Glycan-Interacting Compounds and Methods of Use | SEAGEN INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2019150323-A1 | SPORTS SUPPLEMENTS BASED ON LIQUID CREATINE | OSTOJIC SERGEJ (RS) | 2019-08-08 | — | — | WO | disclosed |
| US-20180327509-A1 | GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE | SEAGEN INC. | 2018-11-15 | — | — | US | disclosed |
| EP-3373969-A1 | GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE | Siamab Therapeutics, Inc. (US) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017083582-A1 | GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE | SIAMAB THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| US-7511164-B2 | Enhanced bioavailability; reacting creatine, fatty acid and thionyl halide | MULTI FORMULATIONS LTD (CA) | 2009-03-31 | — | — | US | disclosed |
| WO-2008101309-A1 | CREATINE-FATTY ACIDS | MULTI FORMULATIONS LTD. (CA) | 2008-08-28 | — | — | WO | disclosed |
| US-20080200723-A1 | CREATINE-FATTY ACIDS | MULTI FORMULATIONS LTD. (CA) | 2008-08-21 | — | — | US | disclosed |
| US-7314945-B1 | Creatine-fatty acids | MULTI FORMULATIONS LTD. (CA) | 2008-01-01 | — | — | US | disclosed |
| US-7226947-B1 | Use of creatine as a fat substitute | ALZCHEM TROSTBERG GMBH (DE) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200723-A1 | CREATINE-FATTY ACIDS | FABP2, FABP3, FABP1 | CA1 742/4885CA2 349/4885NOS3 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.